Difference between revisions of "Zoledronic acid (Zometa)"
Jump to navigation
Jump to search
m |
m (→Dosing) |
||
| Line 7: | Line 7: | ||
==Dosing== | ==Dosing== | ||
| − | *CALGB 70604 results, published as abstract only, demonstrate non-inferiority of 3-month dosing vs. monthly dosing.<ref>Himelstein, Andrew Louis, Qin, Rui, Novotny, Paul J., Seisler, Drew K., Khatcheressian, James L., Roberts, John D., Grubbs, Stephen S., O'Connor, Tracey, Weckstein, Douglas, Loprinzi, Charles L., Shapiro, Charles L. CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. J Clin Oncol (Meeting Abstracts) 2015 33: 9501 [http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9501 link to abstract]</ref> | + | *'''CALGB 70604''' results, published as abstract only, demonstrate non-inferiority of 3-month dosing vs. monthly dosing.<ref>Himelstein, Andrew Louis, Qin, Rui, Novotny, Paul J., Seisler, Drew K., Khatcheressian, James L., Roberts, John D., Grubbs, Stephen S., O'Connor, Tracey, Weckstein, Douglas, Loprinzi, Charles L., Shapiro, Charles L. CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. J Clin Oncol (Meeting Abstracts) 2015 33: 9501 [http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9501 link to abstract]</ref> |
| + | *'''OPTIMIZE-2''' demonstrated non-inferiority between every 4 week and every 12 week dosing in metastatic breast cancer.<ref>Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic | ||
| + | to Bone: The OPTIMIZE-2 Randomized Clinical Trial. JAMA Oncol. 2017 Jul 1;3(7):906-912. [http://jamanetwork.com/journals/jamaoncology/fullarticle/2598744 link to original article][https://www.ncbi.nlm.nih.gov/pubmed/28125763 PubMed]</ref> | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 21:01, 8 August 2017
General information
Class/mechanism: Bisphosphonate, inhibits osteoclast activity and bone resorption/turnover, induces osteoclast apoptosis, and inhibits skeletal calcium release by tumor stimulatory factors.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Dosing
- CALGB 70604 results, published as abstract only, demonstrate non-inferiority of 3-month dosing vs. monthly dosing.[4]
- OPTIMIZE-2 demonstrated non-inferiority between every 4 week and every 12 week dosing in metastatic breast cancer.[5]
Patient drug information
- Zoledronic acid (Zometa) patient drug information (Chemocare)[6]
- Brief patient counseling information can be found in the Zoledronic acid (Zometa) package insert[1]
- Zoledronic acid (Zometa) patient drug information (UpToDate)[7]
Management checklist
- Basic metabolic panel (BMP) including creatinine and calcium, albumin (to calculate corrected calcium), phosphorus, vitamin D 25, bone density, calcium & vitamin D supplementation, dental exam/dental health
Also known as
Acido Zoledronico, Aclasta, Blaztere, Cytozol, Reclast, Servycal, Tianqing YI TAI, Zhuo LAI, Zobone, Zoldonat, Zoledronate, Zoledronate Disodium, Zoledronic Acid, Zomera, Zometa, Zyfoss
References
- ↑ 1.0 1.1 1.2 Zoledronic acid (Zometa) package insert
- ↑ Zoledronic acid (Zometa) package insert (locally hosted backup)
- ↑ Zometa manufacturer's site
- ↑ Himelstein, Andrew Louis, Qin, Rui, Novotny, Paul J., Seisler, Drew K., Khatcheressian, James L., Roberts, John D., Grubbs, Stephen S., O'Connor, Tracey, Weckstein, Douglas, Loprinzi, Charles L., Shapiro, Charles L. CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. J Clin Oncol (Meeting Abstracts) 2015 33: 9501 link to abstract
- ↑ Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. JAMA Oncol. 2017 Jul 1;3(7):906-912. link to original articlePubMed
- ↑ Zoledronic acid (Zometa) patient drug information (Chemocare)
- ↑ Zoledronic acid (Zometa) patient drug information (UpToDate)